Oral anticoagulation – current knowlegde
DOI:
https://doi.org/10.12775/JEHS.2022.12.11.011Keywords
anticoagulant treatment, vitamin K antagonists, direct oral anticoagulants, atrial fibrillationAbstract
Vitamin K antagonists (VKA) and direct oral anticoagulants (DOAC) are two groups of drugs used in the prevention of thromboembolic events. Although DOACs are currently the preferred option in such prophylaxis, there are still indications for the use of VKAs. Thromboembolic episodes may occur as a result of many cardiovascular diseases, inter alia cardiac dysrhythmias. Atrial fibrillation is an arrhythmia that may be asymptomatic or manifested by chest pain, syncope, dyspnea or fatigue. Moreover, it is associated with a high risk of serious complications. An ischemic stroke or myocardial infarction can result from poorly treated AF and may sometimes be the only symptom of an arrhythmia. Therefore, the assessment of a patient's eligibility for anticoagulation therapy is an important element in the prevention of thromboembolic events. Demographic aging and the associated comorbidity may pose a clinical problem in the treatment of atrial fibrillation. The selection of an appropriate anticoagulant therapy should be individualized to the patient's needs.
References
Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014 Apr 25;114(9):1453-68. doi: 10.1161/CIRCRESAHA.114.303211. PMID: 24763464
Maria Trusz-Gluza, Wiktoria Leśniak, Migotanie przedsionków (AF), s.232-243, W: Interna Szczeklika, red. Gajewski P, Medycyna Praktyczna, Kraków 2021
Rienstra M, Lubitz SA, Mahida S, Magnani JW, Fontes JD, Sinner MF, Van Gelder IC, Ellinor PT, Benjamin EJ. Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities. Circulation. 2012 Jun 12;125(23):2933-43.
Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. Circ Res. 2017 Apr 28;120(9):1501-1517. doi: 10.1161/CIRCRESAHA.117.309732. PMID: 28450367; PMCID: PMC5500874.
Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol. 2017 Nov;14(11):627-628. doi: 10.1038/nrcardio.2017.153. Epub 2017 Sep 29. PMID: 28960189.
Grimaldi-Bensouda L, Le Heuzey JY, Ferrières J, Leys D, Davy JM, Martinez M, Dialla O, Smadja D, Nighoghossian N, Benichou J, Nordon C, Touzé E, Abenhaim L. Stroke Prevention by Anticoagulants in Daily Practice Depending on Atrial Fibrillation Pattern and Clinical Risk Factors. Stroke. 2021 Oct;52(10):3121-3131. doi: 10.1161/STROKEAHA.120.032704. Epub 2021 Jul 13. PMID: 34253047.
Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz SA, Magnani JW, Ellinor PT, Seshadri S, Wolf PA, Vasan RS, Benjamin EJ, Levy D. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015 Jul 11;386(9989):154-62. doi: 10.1016/S0140-6736(14)61774-8. Epub 2015 May 7. PMID: 25960110; PMCID: PMC4553037.
Christophersen IE, Ellinor PT. Genetics of atrial fibrillation: from families to genomes. J Hum Genet. 2016 Jan;61(1):61-70. doi: 10.1038/jhg.2015.44. Epub 2015 May 21. PMID: 25994868
Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol. 2005 Dec 7;105(3):315-8. doi: 10.1016/j.ijcard.2005.02.050. PMID: 16274775
Auer J, Scheibner P, Mische T, Langsteger W, Eber O, Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J. 2001 Nov;142(5):838-42. doi: 10.1067/mhj.2001.119370. PMID: 11685172.
Mehra R, Benjamin EJ, Shahar E, Gottlieb DJ, Nawabit R, Kirchner HL, Sahadevan J, Redline S; Sleep Heart Health Study. Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study. Am J Respir Crit Care Med. 2006 Apr 15;173(8):910-6. doi: 10.1164/rccm.200509-1442OC. Epub 2006 Jan 19. PMID: 16424443; PMCID: PMC2662909.
Diouf I, Magliano DJ, Carrington MJ, Stewart S, Shaw JE. Prevalence, incidence, risk factors and treatment of atrial fibrillation in Australia: The Australian Diabetes, Obesity and Lifestyle (AusDiab) longitudinal, population cohort study. Int J Cardiol. 2016 Feb 15;205:127-132. doi: 10.1016/j.ijcard.2015.12.013. Epub 2015 Dec 15. PMID: 26730844.
Heeringa J, Kors JA, Hofman A, van Rooij FJ, Witteman JC. Cigarette smoking and risk of atrial fibrillation: the Rotterdam Study. Am Heart J. 2008 Dec;156(6):1163-9. doi: 10.1016/j.ahj.2008.08.003. Epub 2008 Oct 14. PMID: 19033014.
Wang TJ, Parise H, Levy D, D’Agostino RB, Wolf PA, Vasan RS, Benjamin EJ. Obesity and the risk of new-onset atrial fibrillation.JAMA. 2004; 292:2471–2477. doi: 10.1001/jama.292.20.2471
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke. 1991; 22:983–988.
Khare S. Risk factors of transient ischemic attack: An overview. J Midlife Health. 2016 Jan-Mar;7(1):2-7. doi: 10.4103/0976-7800.179166. PMID: 27134474; PMCID: PMC4832890
Violi F, Soliman EZ, Pignatelli P, Pastori D. Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms. J Am Heart Assoc. 2016 May 20;5(5):e003347. doi: 10.1161/JAHA.116.003347. PMID: 27208001; PMCID: PMC4889200.
Watson, T., Shantsila, E., & Lip, G. Y. (2009). Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. The Lancet, 373(9658), 155–166. doi:10.1016/s0140-6736(09)60040-4
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612. Erratum in: Eur Heart J. 2021 Feb 1;42(5):507. Erratum in: Eur Heart J. 2021 Feb 1;42(5):546-547. Erratum in: Eur Heart J. 2021 Oct 21;42(40):4194. PMID: 32860505.
Zirlik A, Bode C. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. J Thromb Thrombolysis. 2017 Apr;43(3):365-379. doi: 10.1007/s11239-016-1446-0. PMID: 27896543; PMCID: PMC5337242.
Eichinger S. Reversing vitamin K antagonists: making the old new again. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):605-611. doi: 10.1182/asheducation-2016.1.605. PMID: 27913535; PMCID: PMC6142521.
Lucyna Woźnicka-Leśkiewicz, Anna Wolska-Bułach, Andrzej Tykarski Interakcje antykoagulantów z lekami i żywnością — wskazówki dla lekarza praktyka, Choroby Serca i Naczyń 2014;11(2):78-90.
Bertomeu-González V, Anguita M, Moreno-Arribas J, Cequier Á, Muñiz J, Castillo-Castillo J, Sanchis J, Roldán I, Marin F, Bertomeu-Martínez V; FANTASIIA Study Investigators. Quality of Anticoagulation With Vitamin K Antagonists. Clin Cardiol. 2015 Jun;38(6):357-64. doi: 10.1002/clc.22397. Epub 2015 May 11. PMID: 25962838; PMCID: PMC6711074.
Brodsky SV, Nadasdy T, Rovin BH, Satoskar AA, Nadasdy GM, Wu HM, Bhatt UY, Hebert LA. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int. 2011 Jul;80(2):181-9. doi: 10.1038/ki.2011.44. Epub 2011 Mar 9. PMID: 21389969; PMCID: PMC3675881.
Bassand JP, Virdone S, Badoz M, Verheugt FWA, Camm AJ, Cools F, Fox KAA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Misselwitz F, Pieper KS, Turpie AGG, van Eickels M, Kakkar AK. Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. Blood Adv. 2021 Feb 23;5(4):1081-1091. doi: 10.1182/bloodadvances.2020003560. PMID: 33606006; PMCID: PMC7903226.
Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Vanassche T, Potpara T, Camm AJ, Heidbüchel H; External reviewers. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021 Oct 9;23(10):1612-1676. doi: 10.1093/europace/euab065. Erratum in: Europace. 2021 Jun 28;: PMID: 33895845.
Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA,et al..Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.Stroke.2012;43:1511–1517. doi: 10.1161/STROKEAHA.112.650614.
Pfeilschifter W, Lindhoff-Last E, Alhashim A, Zydek B, Lindau S, Konstantinides S, Grottke O, Nowak-Göttl U, von Heymann C, Birschmann I, Beyer-Westendorf J, Meybohm P, Greinacher A, Herrmann E; RADOA-Registry Investigators (Reversal Agent use in patients treated with Direct Oral Anticoagulants or vitamin K antagonists Registry). Intracranial bleeding under vitamin K antagonists or direct oral anticoagulants: results of the RADOA registry. Neurol Res Pract. 2022 May 2;4(1):16. doi: 10.1186/s42466-022-00183-y. PMID: 35491419; PMCID: PMC9059415.
Vang ML, Hvas AM, Ravn HB. Urgent reversal of vitamin K antagonist therapy. Acta Anaesthesiol Scand. 2011 May;55(5):507-16. doi: 10.1111/j.1399-6576.2011.02414.x. Epub 2011 Mar 21. Erratum in: Acta Anaesthesiol Scand. 2011 Jul;55(6):766. PMID: 21418150.
Andrzej Mital, Magdalena Łętowska, Krzysztof Chojnowski, Anna Klukowska, Jacek Musiał, Maria Podolak-Dawidziak, Jarosław Peregud-Pogorzelski, Jacek Treliński, Anetta Undas, Jerzy Windyga, Joanna Zdziarska, Krystyna Zawilska, Polskie zalecenia dotyczące leczenia antagonistami witaminy K, Journal of Transfusion Medicine 2013;6(2):41-47
Goodnough LT, Shander A. How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. Blood. 2011 Jun 9;117(23):6091-9. doi: 10.1182/blood-2010-11-316075. Epub 2011 Mar 16. PMID: 21411756.
Makris M, Watson HG. The management of coumarin-induced over-anticoagulation Annotation. Br J Haematol. 2001 Aug;114(2):271-80. doi: 10.1046/j.1365-2141.2001.02908.x. PMID: 11529844.
Bauer KA. Reversal of antithrombotic agents. Am J Hematol. 2012 May;87 Suppl 1:S119-26. doi: 10.1002/ajh.23165. Epub 2012 Mar 28. PMID: 22460529.
Schwarb H, Tsakiris DA. New Direct Oral Anticoagulants (DOAC) and Their Use Today. Dent J (Basel). 2016 Mar 11;4(1):5. doi: 10.3390/dj4010005. PMID: 29563447; PMCID: PMC5851208.
Schwarb H, Tsakiris DA. New Direct Oral Anticoagulants (DOAC) and Their Use Today. Dent J (Basel). 2016 Mar 11;4(1):5. doi: 10.3390/dj4010005. PMID: 29563447; PMCID: PMC5851208.
Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol. 2012 Feb;26(1):27-32. doi: 10.1111/j.1472-8206.2011.00981.x. Epub 2011 Aug 16. PMID: 21848931.
Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. Clin Pharmacokinet. 2019 Oct;58(10):1265-1279. doi: 10.1007/s40262-019-00775-z. PMID: 31089975; PMCID: PMC6769096.
Stacy ZA, Call WB, Hartmann AP, Peters GL, Richter SK. Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism. Cardiol Ther. 2016 Jun;5(1):1-18. doi: 10.1007/s40119-016-0058-2. Epub 2016 Mar 2. PMID: 26935434; PMCID: PMC4906085.
Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, Patel MR, Wallentin L, Alexander JH, Cecilia Bahit M, Benz AP, Bohula EA, Chao TF, Dyal L, Ezekowitz M, A A Fox K, Gencer B, Halperin JL, Hijazi Z, Hohnloser SH, Hua K, Hylek E, Toda Kato E, Kuder J, Lopes RD, Mahaffey KW, Oldgren J, Piccini JP, Ruff CT, Steffel J, Wojdyla D, Granger CB; COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) Investigators. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation. 2022 Jan 25;145(4):242-255. doi: 10.1161/CIRCULATIONAHA.121.056355. Epub 2022 Jan 5. Erratum in: Circulation. 2022 Feb 22;145(8):e640. PMID: 34985309; PMCID: PMC8800560.
Bezabhe WM, Bereznicki LR, Radford J, Wimmer BC, Salahudeen MS, Garrahy E, Bindoff I, Peterson GM. Oral Anticoagulant Treatment and the Risk of Dementia in Patients With Atrial Fibrillation: A Population-Based Cohort Study. J Am Heart Assoc. 2022 Apr 5;11(7):e023098. doi: 10.1161/JAHA.121.023098. Epub 2022 Mar 18. PMID: 35301852; PMCID: PMC9075457.
Goel N, Jain D, Haddad DB, Shanbhogue D. Anticoagulation in Patients with End-Stage Renal Disease and Atrial Fibrillation: Confusion, Concerns and Consequences. J Stroke. 2020 Sep;22(3):306-316. doi: 10.5853/jos.2020.01886. Epub 2020 Sep 29. PMID: 33053946; PMCID: PMC7568986.
Konieczny KM, Dorian P. Clinically Important Drug-Drug Interactions Between Antiarrhythmic Drugs and Anticoagulants. J Innov Card Rhythm Manag. 2019 Mar 15;10(3):3552-3559. doi: 10.19102/icrm.2019.100304. PMID: 32494414; PMCID: PMC7252850.
Undas A, Drabik L. Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation. Anatol J Cardiol. 2020 Jan;23(1):10-18. doi: 10.14744/AnatolJCardiol.2019.30766. PMID: 31911561; PMCID: PMC7141434.
Desai NR, Cornutt D. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists. Hosp Pract (1995). 2019 Aug;47(3):113-122. doi: 10.1080/21548331.2019.1643728. Epub 2019 Jul 29. PMID: 31317796.
Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, Wirth D, Kaatz S. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. Am J Hematol. 2019 Jun;94(6):697-709. doi: 10.1002/ajh.25475. Epub 2019 Apr 16. PMID: 30916798.
White K, Faruqi U, Cohen AAT. New agents for DOAC reversal: a practical management review. Br J Cardiol. 2022 Jan 12;29(1):1. doi: 10.5837/bjc.2022.001. PMID: 35747314; PMCID: PMC9196076.
Crowther, Mark, Cuker, Adam Jak odwrócić krwawienie u chorych stosujących bezpośrednie doustne antykoagulanty? Kardiologia Polska (Polish Heart Journal)Vol 77, Supp. I (2019), p. 103 – 114
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Anna Karaś, Kinga Kawałko, Krzysztof Bielewicz, Anna Chmura, Antonina Głodek
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 390
Number of citations: 0
